Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to buy a great stock on the cheap. The post At a bargain-basement valuation now, ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...